Metabolic

Featured Article

PCSK9 Inhibition: Benefits Outweigh Risks in Patients With Diabetes

PCSK9 Inhibition: Benefits Outweigh Risks in Patients With Diabetes

Statin therapy is the first line of defense against high LDL-C and the risk for atherosclerotic cardiovascular disease, the leading cause of morbidity and mortality in individuals with diabetes.

Latest Features

PCSK9 Inhibition: Benefits Outweigh Risks in Patients With Diabetes

PCSK9 Inhibition: Benefits Outweigh Risks in Patients With Diabetes

Statin therapy is the first line of defense against high LDL-C and the risk for atherosclerotic cardiovascular disease, the leading cause of morbidity and mortality in individuals with diabetes.

Clinician Perspective: Examining the Link Between Antipsychotics and Diabetes

Clinician Perspective: Examining the Link Between Antipsychotics and Diabetes

Endocrinologist Kevin M. Pantalone, DO, and psychiatrist Christian Kohler, MD, discuss the risk associated with the use of antipsychotic medications in individuals with type 2 diabetes.

Antidiabetic Drugs and Cardiovascular Risk: Expert Perspectives

Antidiabetic Drugs and Cardiovascular Risk: Expert Perspectives

Although many of the newer antidiabetic drugs have demonstrated favorable outcomes in clinical trials, some have also been associated with increased risk of adverse CV outcomes.

Semaglutide May Be Useful for Treating Obesity in People Without Diabetes

Semaglutide May Be Useful for Treating Obesity in People Without Diabetes

In combination with dietary and physical activity counseling, all semaglutide doses from 0.05-0.4 mg daily were tolerated and resulted in dose-related reductions in body weight among people with obesity without diabetes.

Cardiovascular Risk Factors in Cross-Sex Hormone Therapy: Expert Opinion

Cardiovascular Risk Factors in Cross-Sex Hormone Therapy: Expert Opinion

In a meta-analysis of cross-sex hormone therapy use in transgender individuals, researchers found that transgender women may have a greater risk for CVD mortality vs cisgender women in the general population.

Lowering LDL Cholesterol HIV: Pitavastatin vs Pravastatin

Lowering LDL Cholesterol HIV: Pitavastatin vs Pravastatin

Pitavastatin had greater low-density lipoprotein-lowering effects than pravastatin.

New Recommendation for Glucose-Lowering Drug Clinical Trials

New Recommendation for Glucose-Lowering Drug Clinical Trials

The International Hypoglycaemia Study Group now recommends that glucose levels lower than 3.0 mmol/L (54 mg/dL) be documented in clinical trials of glucose-lowering drugs.

Physical Activity for Diabetes: ADA Updated Guidelines

Physical Activity for Diabetes: ADA Updated Guidelines

Physical activity guidelines were updated for patients with type 2 diabetes, type 1 diabetes, and prediabetes.

PCSK9 Inhibitor Alirocumab Associated With 75% Reduction in Apheresis

PCSK9 Inhibitor Alirocumab Associated With 75% Reduction in Apheresis

Among patients with heterozygous familial hypercholesterolemia, alirocumab was associated with a 75% reduction in lipoprotein apheresis compared with placebo.

Cardiovascular Safety of Naltrexone Plus Bupropion Obesity Treatment Uncertain

Cardiovascular Safety of Naltrexone Plus Bupropion Obesity Treatment Uncertain

Findings from the LIGHT trial did not establish the prespecified margin of noninferiority, defined as a hazard ratio of 1.4, after unplanned early termination.

Latest News

Ezetimibe Plus Statin Therapy Reduces Ischemic Risk in Polyvascular Disease, T2D

Ezetimibe Plus Statin Therapy Reduces Ischemic Risk in Polyvascular Disease, T2D

The addition of ezetimibe to simvastatin reduced ischemic risk compared with placebo, with consistent relative risk reductions in patients with and without polyvascular disease.

ACC Releases Consensus Decision Pathway for CVD Risk Reduction in T2D and ASCVD

ACC Releases Consensus Decision Pathway for CVD Risk Reduction in T2D and ASCVD

The American College of Cardiology published an expert consensus statement regarding decision considerations for novel cardiovascular risk reduction therapies in patients with type 2 diabetes and atherosclerotic cardiovascular disease.

Simvastatin Improves Platelet Activation Markers in Primary Hypercholesterolemia

Simvastatin Improves Platelet Activation Markers in Primary Hypercholesterolemia

In patients with primary hypercholesterolemia, short-term treatment with simvastatin improved the lipid profile and exerted a beneficial effect on a wide range of proatherogenic and prothrombotic parameters.

Skin Disease and Metabolic Syndrome: Early Warning Signs of a Greater Problem

Skin Disease and Metabolic Syndrome: Early Warning Signs of a Greater Problem

Skin disorders, particularly those with known inflammatory mechanisms, may be considered potential early markers for the development of insulin resistance leading to metabolic syndrome, type 2 diabetes, and cardiovascular disease.

Statin-Induced Myalgia Unrelated to Muscle Coenzyme Q10 Level

Statin-Induced Myalgia Unrelated to Muscle Coenzyme Q10 Level

Statin therapy is associated with reduced mitochondrial complex II-linked respiration, and statin-induced myalgia is coupled to an increased intrinsic mitochondrial respiratory function, while intramuscular [coenzyme Q10] levels are unaltered.

Predicting Progression of Cardiovascular Autonomic Neuropathy in Type 2 Diabetes

Predicting Progression of Cardiovascular Autonomic Neuropathy in Type 2 Diabetes

Hyperglycemia, obesity, and hypertriglyceridemia are negatively related to cardiovascular autonomic neuropathy indices.

Evolocumab Price Decreased to Reduce Patient Out-of-Pocket Costs

Evolocumab Price Decreased to Reduce Patient Out-of-Pocket Costs

Repatha is a proprotein convertase subtilisin/kexin type 9 inhibitor.

Liraglutide Labeling Updated With Cardiovascular Safety Data

Liraglutide Labeling Updated With Cardiovascular Safety Data

The randomized, double-blind, placebo-controlled, parallel-group study (N=9340) evaluated the time from randomization to first occurrence of major adverse CV events (MACE) (non-fatal heart attack, non-fatal stroke, CV death) in patients treated with liraglutide 1.8mg once daily or placebo.

Modifiable CV Risk Factors Within Healthy Range Indicative of CV Morphology, White Matter Lesions

Modifiable CV Risk Factors Within Healthy Range Indicative of CV Morphology, White Matter Lesions

In multivariable models, associations were observed between cardiovascular risk factors and cerebrovascular morphology, as well as white matter hyperintensity count.

PCSK9 Inhibitor Tolerability Examined in Patients With Self-Reported Statin Intolerance

PCSK9 Inhibitor Tolerability Examined in Patients With Self-Reported Statin Intolerance

The study utilized patient-reported side effects to determine the tolerability of the PCSK9 inhibitors evolocumab and alirocumab.

Sign Up for Free e-Newsletters